More topics

Limited coverage drugs – infliximab for PsA, AS, Ps

Last updated on January 21, 2025

 

PharmaCare covers infliximab biosimilar products for psoriatic arthritis (PsA), ankylosing spondylitis (AS), plaque psoriasis (PsO), Crohn's disease (CD), ulcerative colitis (UC) and rheumatoid arthritis (RA).

Return to Special Authority drug list

Generic name

infliximab

Brand name

Avsola™, Inflectra©, Renflexis©

Strength & form

100 mg/vial powder for solution

Special Authority criteria

Approval period

For the treatment of psoriatic arthritis (PsA) according to established criteria as described on Special Authority request forms below and eForm application, when requested by a rheumatologist.

Initial: 1 year

Renewal: 1 year to indefinite

For the treatment of ankylosing spondylitis (AS) according to established criteria as described on Special Authority request forms below and eForm application, when requested by a rheumatologist.

Initial: 1 year

Renewal: 1 year to indefinite

For the treatment of moderate to severe psoriasis (Ps) according to established criteria as described on Special Authority request forms below and eForm application, when requested by a dermatologist

Initial (induction period): 3 doses

Renewal: 1 year

Practitioner exemptions

  • None

Special notes

  • PharmaCare covers a maximum of 56 days' supply of intravenous (IV) infliximab per fill. Eligible dosing amounts can be seen on the Special Authority Request form for the indication and on an approved Special Authority Request. One infusion (dose) usually provides treatment for 56 days or less

Special Authority request forms

Psoriatic arthritis

Ankylosing spondylitis

Psoriasis